Proceeding contribution from Brian Iddon (Labour) in the House of Commons on Thursday, 8 December 2005. It occurred during Estimates day on Department of Health.
Department of Health
I must challenge that statement. Evidence was given at a meeting in the House last night that packages of parallel traded products contained drugs that were not the same as the drugs made by the professional company that had discovered them. Such products contained impurities that could cause serious side effects and in some cases death in the patient.
Secondary information
- Type
- Proceeding contribution
- Reference
- 440 c1034
- Session
- 2005-06
- Chamber / Committee
- House of Commons chamber
- Subjects
- Advertising Licensing Expenditure Drugs Government departments Industry Prescription drugs Department of Health Medicines and Healthcare products Regulatory Agency Research Regulation Safety National Institute for Health and Care Excellence Registration Clinical trials
- Link
- View this Proceeding contribution on www.publications.parliament.uk
Librarians' tools
- Timestamp
- 2025-11-24 15:50:31 +0000
- URI
- http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285116
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285116
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285116